07.06.2018 • NewsAscendDede Willams

Ascend Adding 220,000 t to PA 6.6 Chain

Ascend Adding 220,000 t to PA 6.6 Chain (c) Ascend
Ascend Adding 220,000 t to PA 6.6 Chain (c) Ascend

Houston, Texas-based polyamide 6.6 specialist Ascend Performance Materials has provided details of the planned 10-15% expansion of its value chain – acrylonitrile, adiponitrile, hexamethylene diamine, adipic acid and polymers – announced last year.

The company that regards itself as the world’s largest fully integrated producer of PA 6.6 resin said last year that global demand for its product range across diverse application was growing at 3-4% annually.

Up to 2022, Ascend will add a total of 220,000 t/y to its existing acrylonitrile (ADN) capability of around 400,000 t/y before the project began. The first expansion stage at the US company’s Decatur, Alabama, facility was completed at the end of 2017, adding 50,000 t/y of new capacity. A second 40,000 t/y expansion stage is planned to be completed by the end of 2018, with an additional 180,000 t/y scheduled to be in place by 2022.

CEO Phil McDivitt said Ascend is “committed to supporting the growth of the nylon 6,6 chain globally and has consistently increased capacity throughout the chain as demand increased.” With its latest fifth generation ADN technology, he said the company is able to add capacity without extensive down time.

Interview

Stability in Motion
Strategic Response to a Shifting Pharma Landscape

Stability in Motion

Stefan Oelrich, Member of the Board of Management and President Pharmaceuticals, Bayer, discusses navigating external volatility, reshaping its internal structures, and investing in future-ready capabilities to ensure sustainable growth.

Free Expert Insights

Dual‑Targeting Breakthroughs
Advancements in Bispecific Antibody Development

Dual‑Targeting Breakthroughs

Unlock the latest breakthroughs in bispecific antibody development! Download Wiley’s free Expert Insights eBook to explore cutting-edge dual-targeting strategies, advanced purification methods, and bioanalytical technologies transforming immunotherapy and cancer treatment.

most read